Max Kates, MD

An expert discusses how treatment decisions must balance short-term burden with long-term benefits while avoiding protocol-driven step therapy requirements, as future comparative effectiveness trials and real-world evidence will better inform individualized patient care strategies.

An expert discusses how long-term durability data at one to two years, rather than short-term three-month responses, provides greater confidence in treatment selection and influences formulary decisions based on comparative efficacy and toxicity profiles.

An expert discusses how BCG-unresponsive NMIBC patients have heterogeneous clinical needs requiring individualized treatment strategies, while P&T committees evaluate new therapies by assessing unmet needs and comparing real-world evidence across single-arm trials.